Up to date, four classes of biologics targeting inflammatory cytokines are used to treat psoriasis: TNF-α inhibitors; IL-12/23 inhibitors; IL-17 inhibitors; and IL-23 inhibitors [18]. This evidence concerns the gene TNF and psoriasis.